Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) reported a net loss of $22.6 million, or $0.64 per share, for Q1 2022, compared to a net income of $29.2 million for the same period in 2021, largely due to a one-time gain last year. Cash and equivalents stand at $153.5 million post-a $20.8 million stock sale, expected to fund operations into Q4 2024. Significant milestones anticipated include an EUA application for peginterferon lambda for COVID-19 and topline data from the D-LIVR study for HDV by year-end.
- Pro forma cash position of $153.5 million expected to sustain operations into Q4 2024.
- Upcoming submission of EUA application for peginterferon lambda to treat COVID-19.
- Topline data from the D-LIVR Phase 3 study of lonafarnib for HDV expected by end of 2022.
- Net loss of $22.6 million in Q1 2022 compared to prior year's income.
- Decline in net product sales of Zokinvy from $3.6 million in Q1 2021 to $2.7 million in Q1 2022.
- Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022
- Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End
- Zokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022
- Phase 3 Avexitide Congenital Hyperinsulinism Program Initiation Planned by Year End
- Strong Cash Position:
$153.5M Pro Forma Cash
PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2022 and provided a business update.
"We are laser focused on executing our development and commercialization strategies and anticipate significant value-creating milestones this quarter, including the submission of an Emergency Use Authorization application for lambda to treat COVID-19 as well a CHMP opinion on our Zokinvy MAA for progeria," said David Cory, President and CEO, Eiger. "In parallel, we continue to advance our clinical pipeline and remain on track to announce topline data from our landmark Phase 3 D-LIVR study of lonafarnib for HDV this year."
Business Highlights
Peginterferon Lambda for COVID-19 Infection
- Actively engaging with FDA on Emergency Use Authorization (EUA) application
- Preparing to submit EUA application and publish full dataset
- Gating component for EUA application is full data analyses from TOGETHER team which is in process and nearing completion
- Announced Phase 3 TOGETHER study topline data in mid-March
- Novel mechanism of action, likely agnostic to variants
- Second largest outpatient study to date in COVID-19 (N>1,900)
- Single-dose peginterferon lambda for COVID-19 reduced risk of hospitalization or ER visits greater than six hours by
50% in a predominantly vaccinated population - Highly superior compared to placebo, with a probability of superiority of
99.91% on the primary endpoint - Primary endpoint of reduced risk of hospitalization or ER visits achieved across multiple SARS-CoV-2 variants
Hepatitis Delta Virus Platform
Lonafarnib for HDV
- First-in-class, oral prenylation inhibitor
- D-LIVR Phase 3 study with potential approval of two lonafarnib-based regimens
- Oral lonafarnib/ritonavir and in combination with peginterferon alfa
- Topline data planned by end of 2022
Peginterferon Lambda for HDV
- First-in-class well-tolerated interferon
- Potential to be interferon of choice in HDV combination therapies
- LIMT-2 Phase 3 study of peginterferon lambda monotherapy
- Enrolling patients, targeting N=150
Combination of Peginterferon Lambda and Lonafarnib for HDV
- Combination of Eiger's two proprietary HDV therapies in development
- LIFT-2 Phase 2 study in collaboration with National Institutes of Health initiating in 2022
- Single arm study (N=30), 48 weeks of treatment with 24 weeks of follow-up
Zokinvy® (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies
- CHMP opinion expected in Q2 2022
Avexitide for Rare Metabolic Disorders
- Planned Phase 3 congenital hyperinsulinism (HI) program to be initiated by end of 2022
- Granted Breakthrough Therapy designation for HI
- Granted Rare Pediatric Disease designation for HI – Priority Review Voucher eligible
- Reported positive Phase 2 data from Children's Hospital of Philadelphia (CHOP) published in Diabetes Care
Corporate
- Strengthened leadership team with new biopharma executive hires
- Chris Kurtz hired as Chief Technical Officer
- Sarah Mathieson hired as Senior Vice President, Corporate Affairs
First Quarter 2022 Financial Results
Cash, cash equivalents, and total investments as of March 31, 2022 totaled
Net product sales of Zokinvy were
Cost of sales was approximately
Research and Development expenses were
Selling, General and Administrative expenses were
Total operating expenses include non-cash expenses of
The Company reported a net loss of
As of March 31, 2022, the company had 40.5 million of common shares outstanding.
Conference Call
At 4:30 PM Eastern Time today, May 5, 2022, Eiger will host a conference call to discuss its financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 2392544. The webcast will be archived and available for replay for at least 90 days after the event.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and is preparing to submit an emergency use authorization application to FDA based on positive results from the investigator sponsored Phase 3 TOGETHER study. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, regulatory objectives, business strategy and plans and objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our anticipated significant milestones in 2022; the timing of our ongoing and planned clinical development; the sufficiency of our cash, cash equivalents and investments to fund our operations; the likelihood of timely submitting and obtaining an Emergency Use Authorization from the FDA for peginterferon lambda for COVID-19; expectations regarding the timing and availability of topline data from our Phase 3 D-LIVR study in HDV; the ability to fully enroll the Phase 3 LIMT-2 study; commencing a Phase 3 study of avexitide in congenital hyperinsulinism; the approval of Zokinvy in jurisdictions outside of the U.S., including the EU; our capability to provide sufficient quantities of any of our product candidates, including peginterferon lambda, to meet anticipated full-scale commercial demands; our ability to finance the continued advancement of our development pipeline products; and the potential for success of any of our product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the "Risk Factors" sections in the Annual Report on Form 10-K for the year ended December 31, 2021 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
Eiger BioPharmaceuticals Inc. | |||||
Quarter Ended | Year Ended | ||||
March 31, | December 31, | ||||
2022 | 2021(1) | ||||
ASSETS | |||||
Cash and cash equivalents | $ 46,562 | $ 22,221 | |||
Short-term debt securities | 86,155 | 66,594 | |||
Accounts receivable | 2,287 | 2,576 | |||
Inventories | 1,910 | 2,612 | |||
Prepaid expenses and other current assets | 10,442 | 9,361 | |||
Total current assets | 147,356 | 103,364 | |||
Long-term debt securities | - | 17,262 | |||
Property and equipment, net | 545 | 613 | |||
Operating lease right-of-use assets | 521 | 653 | |||
Other assets | 4,907 | 4,510 | |||
Total assets | $ 153,329 | $ 126,402 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
Current liabilities | $ 36,612 | $ 29,901 | |||
Other liabilities | 19,450 | 24,102 | |||
Stockholders' equity | 97,267 | 72,399 | |||
Total liabilities and stockholders' equity | $ 153,329 | $ 126,402 | |||
- | - |
(1) | Derived from the audited financial statements, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. |
Eiger BioPharmaceuticals Inc. | ||||||
Condensed Consolidated Statements of Operations Financial Data | ||||||
(in thousands, except per share and share amounts) | ||||||
Three Months Ended | ||||||
March 31, | ||||||
(unaudited) | ||||||
2022 | 2021 | |||||
Product revenue, net | $ 2,673 | $ 3,646 | ||||
Costs and operating expenses: | ||||||
Cost of sales | 110 | 53 | ||||
Research and development(1) | 17,570 | 13,842 | ||||
Selling, general and administrative(1) | 6,813 | 5,564 | ||||
Total operating expenses | 24,493 | 19,459 | ||||
Loss from operations | (21,820) | (15,813) | ||||
Interest expense | (886) | (885) | ||||
Interest income | 45 | 51 | ||||
Other income (expense), net | 27 | 45,914 | ||||
Income (loss) before provision for taxes | (22,634) | 29,267 | ||||
Provision for income taxes | 9 | 19 | ||||
Net loss | $ (22,643) | $ 29,248 | ||||
Net income (loss) per common share: | ||||||
Basic | $ (0.64) | $ 0.86 | ||||
Diluted | $ (0.64) | $ 0.85 | ||||
Weighted-average common shares outstanding: | ||||||
Basic | 35,253,147 | 33,886,896 | ||||
Diluted | 35,253,147 | 34,220,895 | ||||
(1) | Includes stock-based compensation expense of: | |||||
Three Months Ended | ||||||
March 31, | ||||||
2022 | 2021 | |||||
Research and development | $ 625 | $ 391 | ||||
General and administrative | 1,422 | 1,158 | ||||
Total stock-based compensation expense | $ 2,047 | $ 1,549 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-business-update-301541275.html
SOURCE Eiger BioPharmaceuticals, Inc.
FAQ
What were Eiger's financial results for Q1 2022?
What is Eiger's cash position as of Q1 2022?
What milestones is Eiger expecting in 2022?